Project Grant R15CA306651
Award Date
7/11/25
Completion Date
6/30/28
Dollars Obligated
$477K
Federal Agency
National Cancer Institute
Awardee
Barnard College (LPQ1NHRK78M9)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, NY 10027, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
This Project Grant award of $1,349,322, provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research at the University of Pittsburgh to study how the Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates cellular metabolic pathways and the S-adenosylmethionine (SAM) cycle to maximize both latent and lytic viral infections. The researchers aim to identify KSHV-regulated N6-methyladenosine (m6A) modifications on cellular mRNA that reprogram the SAM...
This Project Grant award of $877,104 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the interactions between Kaposi's sarcoma-associated herpesvirus (KSHV), mononuclear phagocytes, and B cells, and how KSHV establishes long-term latency in B cells. The research, conducted by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will use computational...
This federal Project Grant award of $185,513, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), aims to develop O'PROTAC-based degraders that specifically target the KSHV-encoded LANA oncoprotein to interfere with the survival of Kaposi's sarcoma-associated herpesvirus (KSHV)-positive tumor cells. The award, with a project period from Nov 2024 to Oct 2026, is funding research at the University of Arkansas for Medical...
This Project Grant award of $157,000 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to unveil a novel mechanism of oncovirus-induced carcinogenesis. The primary awardee, Rutgers, The State University of New Jersey, will conduct long-read sequencing on hepatitis B virus (HBV)-positive tumors and cell lines to fully map HBV integrations and identify HBV integration-bridged chromosomal translocation events. This research aims to validate...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is providing $1,337,014 over approximately 5 years starting September 1, 2024 to investigate the mechanisms by which Kaposi's Sarcoma-Associated Herpesvirus (KSHV) manipulates cellular metabolism to facilitate viral replication and tumor growth. The key research objectives are to: 1) Determine how KSHV's viral cyclin protein...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), provides $583,289 to the University of Arkansas for Medical Sciences to conduct research on the epigenetic regulation of Kaposi's sarcoma-associated herpesvirus (KSHV) latency. The research aims to advance understanding of how KSHV, which causes several AIDS-defining malignancies including Kaposi's sarcoma, can...
This Project Grant award of $188,169.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The key objectives are to complete proof-of-concept studies evaluating the biological activity and efficacy of the AAV vector in killing cancer cells through in vitro assays and xenograft mouse models. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $170,640 in funding to the Dana-Farber Cancer Institute, Inc. (DFCI) from July 1, 2025 to June 30, 2027. The grant supports research to investigate the role of histone cleavage in breast cancer, specifically focusing on how the KDM4C histone demethylase drives tumor growth by preventing proteolytic cleavage of the histone H3 N-terminal tail by cathepsin L. The research aims to...